ArticleBMC cancer2025
Heterogeneity of metastatic gastric cancer: solitary non-regional lymph node metastasis and solitary lung metastasis showed better survival outcomes than other metastatic patterns.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Serum NGAL and G-CSFR as Predictive and Prognostic Biomarkers for Trastuzumab-Based Therapy in HER2-Positive Gastric Cancer: A Retrospective Study.Cancer management and research · 2026Article
- Distant metastasis risk and prognosis in elderly gastric cancer patients after neoadjuvant chemotherapy and surgery.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundAlthough metastatic gastric cancer has remarkably poor prognosis, a small group of patients achieved relatively favorable survival outcomes due to the disease's variable biological behavior. The study aimed to investigate the impact of metastatic patterns on survival outcomes of metastatic gastric cancer patients.
methodsPatients with distant metastatic (M1) gastric cancer in the China National Cancer Center between January 1999 to December 2019 were retrospectively reviewed. Univariate and multivariate cox regression analyses tested the relationship between metastatic patterns and survival.
resultsA total of 2,042 patients with definitive information on metastatic organs were included in the study. Liver (772 [37.9%]), peritoneum (765 [37.6%]), and non-regional lymph node (692 [34.0%]) were the most three common metastasis organs for metastatic gastric cancer patients in our study. The median survival time of patients with metastatic gastric cancer was 15.4 months. For patients with solitary non-regional lymph node metastasis, the 2-year and 5-year overall survival (OS) rates were notably high at 48.12 and 24.55%, respectively. Patients with solitary lung metastasis demonstrated similarly favorable survival outcomes, with 2-year and 5-year OS rates reaching 46.45 and 16.02%. However, patients with multi-organ metastases faced the poorest prognosis among those with metastatic gastric cancer, with 26.98% of them surviving more than 2 years, and only 8.35% surviving more than 5 years. In multivariate cox regression analyses, solitary non-regional lymph node metastasis [multiple organs Ref; hazard ratio (HR) 0.636, 95% CI 0.507-0.798, P < 0.001] and solitary lung metastasis (multiple organs Ref; HR 0.535, 95% CI 0.336-0.852, P = 0.008) were independent beneficial prognostic factors in metastatic gastric cancer patients.
conclusionsGastric cancer patients with solitary non-regional lymph node metastasis and solitary lung metastasis showed better survival outcomes than other metastatic gastric cancer patients. Sub-classifying metastatic gastric cancer based on metastatic organs is recommended, which could assist in forecasting survival outcomes and facilitating individualized treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.